Introduction {#s1}
============

Glioblastoma (GBM) is the most common malignant tumor of the central nervous system (CNS) and causes a high mortality rate ([@B40]; [@B50]). Although many new therapies have improved the clinical outcome and more clinical trials have demonstrated the high efficacy in treating GBM, the survival rate of GBM patients is still low. GBM is a complex disease to tackle with a median survival period of approximately 14 months, and a 5-year survival rate of 5% ([@B51]; [@B26]; [@B42]). Prognostic biomarkers have been showing great roles in cancer patient management and may guide targeted therapies. Therefore, it is greatly needed to investigate prognostic biomarkers in GBM.

Previous studies have reported some prognostic biomarkers in GBM, such as gene mutation of gene *IDH* and *PTEN*, and expression variation of gene *CD133* ([@B61]; [@B5]; [@B39]). However, these biomarkers have not been translated to clinical applications due to the lack of independent validation. In addition, due to the molecular heterogeneity among GBMs and limited patient samples ([@B37]; [@B2]; [@B4]), the prognostic behavior of a certain biomarker may be inconsistent or even contradictory between different reports. In other words, cross population validation in a larger patient cohort is critical for evaluating the prognostic biomarker.

In current work, we collected the gene expression profiles and clinical information of 684 GBM patients from seven independent cohorts obtained from TCGA, GEO and CGGA. We developed a user-friendly web server, OSgbm, to analyze the prognostic value of genes of interests. With this web server, it would facilitate researchers and clinicians to screen, develop and validate new prognostic biomarkers in GBM.

Methods {#s2}
=======

Datasets Collection {#s2_1}
-------------------

GBM datasets are from three major data sources. First, level-3 gene expression profiling data (HiSeqV2) and clinical information of GBM samples were downloaded from TCGA on April 2018 (<https://portal.gdc.cancer.gov/>). Second, four cohorts (≥30 cases) with available gene expression profiles and clinical survival information were collected from GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). Third, two GBM cohorts were gathered from CGGA (<http://www.cgga.org.cn/>). After an initial filtration and quality check (with available gene expression profiling data and clinical survival information), 153 samples from TCGA, 276 samples from GEO, and 255 samples from CGGA were included for the following database and web server construction. The histology of recurrent GBM (rGBM) were included in GSE7696 (10 samples), GSE42669 (11 samples), CGGAarray (9 samples) and CGGAseq (22 samples) datasets. Two CGGA datasets also included 20 samples of secondary GBM (sGBM).

System Implementation and Server Set-Up {#s2_2}
---------------------------------------

OSgbm is a web-based tool which uses J2EE (Java 2 Platform Enterprise Edition) architecture as we previously described ([@B54]; [@B55]; [@B58]; [@B65]). The gene expression and clinical data were integrated in the background database, which was handled by a MySQL server. Dynamic web interfaces were written in HTML 5.0 and hosted by Tomcat on Windows Server. Using OSgbm requires a HTML 5.0-compliant browser with JavaScript enabled, but does not require any particular visual plug-in tool. Since the web server was designed for users with no specialized bioinformatics skills, we propose 'out-of-the-box' data. The input of OSgbm web server is official gene symbol. For the "Data Source: Combined" option, as all the datasets used in OSgbm already have been published, processed and normalized well, in order to avoid of the batch effect and platform biases among these datasets, we first stratify the patients into high- and low-expression group for the input gene in each dataset, and then merged relative patients from high- and low-expression group from each dataset into a combined high-expression group (Upper group in the Kaplan--Meier plot) and a combined low-expression group (Lower group in the Kaplan--Meier plot) for the analysis of Kaplan--Meier plot and log-rank test. The statistical analyses of input were performed with R package: KM curves with Hazard ratio (HR, 95% confidence interval) and log-rank *p* value were calculated by R package 'survival'. OSgbm is available at <http://bioinfo.henu.edu.cn/GBM/GBMList.jsp>.

Validation of Previously Reported Prognostic Biomarkers {#s2_3}
-------------------------------------------------------

A PubMed search was performed to identify previously reported GBM prognostic biomarkers, using keywords 'glioblastoma', 'survival' and 'biomarker'. Totally, 53 prognostic biomarkers were identified from 2013 publications. The flow chart of biomarker collection was showed in [**Figure S1**](#SM1){ref-type="supplementary-material"}. The prognostic values of these published biomarkers were analyzed in either a form of combined cohorts of all GBM patients or in a single cohort in our database.

Results {#s3}
=======

The Clinical Characteristics of GBM Datasets Used in OSgbm {#s3_1}
----------------------------------------------------------

In OSgbm, we included a total of 684 unique GBM samples from seven datasets, including one TCGA cohort, four GEO cohorts and two CGGA cohorts. The survival information includes overall survival (OS), disease specific survival (DSS), disease free interval (DFI) and progression free interval (PFI) ([@B29]). The confounding clinical factors, such as age, grade, gender, histology and treatment regimens were included as well. Clinical characteristics of these datasets in the OSgbm were presented in [**Table 1**](#T1){ref-type="table"}. All of the 684 patients have OS data, and the median OS time was 13.44 months, while 153 GBM patients from TCGA cohort have four above mentioned survival terms (OS, DSS, DFI and PFI). The median age of all the patients is 50 years. The death rate is 78.49%. A large proportion of the patients are in grade IV, especially in the two CGGA datasets (99.28% and 100%, respectively).

###### 

Clinical characteristics of each GBM dataset used in OSgbm.

  -------------------------------------------------------------------------------------------------------------------------
  Data\       Sample\    Median Age (years)   Death\   OS Median\   Gender\     Grade\                  Survival\
  Source      Size (n)                        (%)      (years)      (male, %)   (I/II/III/IV, %)        Terms
  ----------- ---------- -------------------- -------- ------------ ----------- ----------------------- -------------------
  TCGA        153        60                   79.08    11.90        64.71       --                      OS, DSS, DFI, PFI

  GSE7696     80         52                   81.25    15.58        73.75       --                      OS

  GSE4412     85         42                   69.41    12.97        37.65       0/0/30.59/69.41         OS

  GSE42669    57         51                   80.70    14.93        52.63       --                      OS

  GSE30472    54         --                   88.89    15.72        --          3.7/12.96/29.63/53.71   OS

  CGGAseq     128        48                   66.67    9.55         65.22       0/0/0.72/99.28          OS

  CGGAarray   127        47                   83.46    13.43        62.20       0/0/0/100               OS

  Total       684        50                   78.49    13.44        59.36       --                      --
  -------------------------------------------------------------------------------------------------------------------------

Set-Up of OSgbm Web Server {#s3_2}
--------------------------

The main function of OSgbm web server is to evaluate and determine the prognostic value of the quested genes. The users start by typing the gene symbol and choosing one dataset of interest or the combined dataset with pooling all the datasets together. To measure the association between a quested gene and survival, GBM samples are categorized according to the median (or other appropriate cutoff value, such as Trichotomy, Quartile) of the selected gene, and KM analysis is used to compare the outcomes between groups ([@B59]). The user could limit the analysis in a subgroup of the patients by setting the age range, grade, gender and so on. Once the gene symbol is input and clinical characters are chosen, OS, DSS, DFI or PFI of each stratified group can be measured and analysis results will be available on the output web page. The prognostic value of each given gene is determined by HR (95% CI) and log-rank *p* value.

Validation of Previously Reported GBM Prognostic Biomarkers {#s3_3}
-----------------------------------------------------------

To determine the performance of this online tool, 53 previously published GBM prognostic factors collected as the procedure shown in [**Figure S1**](#SM1){ref-type="supplementary-material"} and then they were evaluated in OSgbm ([**Table 2**](#T2){ref-type="table"}, [**Figure 1**](#f1){ref-type="fig"}) ([@B47]; [@B25]; [@B23]; [@B1]; [@B48]; [@B43]; [@B11]; [@B13]; [@B27]; [@B45]; [@B53]; [@B56]; [@B3]; [@B19]; [@B34]; [@B41]; [@B67]; [@B33]; [@B35]; [@B60]; [@B66]; [@B8]; [@B38]; [@B49]; [@B49]; [@B62]; [@B63]; [@B14]; [@B15]; [@B16]; [@B20]; [@B22]; [@B24]; [@B28]; [@B30]; [@B32]; [@B36]; [@B46]; [@B57]; [@B64]; [@B6]; [@B7]; [@B9]; [@B10]; [@B12]; [@B17]; [@B21]; [@B31]; [@B44]; [@B52]; [@B18]). OS was selected as the survival term. Among these prognostic genes, 51 of them showed significant prognostic ability in a large-scale combined cohort (33 genes) or in single cohort (18 genes), which were consistent with the prognostic value reported in the literature. The remaining two genes (*IGF1R* and *PCBP2*) display significant prognostic values in OSgbm, but is contradictory to what was reported in the literatures. Both of them were shown as favorable prognostic biomarkers in OSgbm but were reported to be unfavorable GBM prognostic biomarkers in previous reports ([**Table 2**](#T2){ref-type="table"}) ([@B33]; [@B30]).

###### 

Validation of previously reported prognostic biomarkers in OSgbm.

  Gene symbol   Validation results         Literature data                                                                                          
  ------------- -------------------------- ----------------- ------------------------ ----------- ----------------------- --------- ----- --------- ----------
  *PROM1*       2.412 (1.040--4.174)       0.007             Upper 25% vs Lower 25%   GSE7679     2.39 (1.77--3.23)       \<0.001   656   mRNA      ([@B62])
  *SRGN*        2.371 (1.256--4.477)       0.008             Upper 25% vs Lower 25%   CGGAseq     --                      0.037     504   mRNA      ([@B46])
  *EDNRB*       2.272 (1.115--4.627)       0.024             Upper 25% vs Lower 75%   GSE30472    2.86 (1.12--7.34)       0.031     25    Protein   ([@B52])
  *PSMB4*       2.074 (1.187--3.626)       0.010             Upper 25% vs Lower 25%   CGGAseq     --                      \<0.001   77    Protein   ([@B9])
  *WNT6*        2.035 (1.098--3.770)       0.024             Upper 25% vs Lower 25%   CGGAseq     --                      0.004     16    Protein   ([@B17])
  *DPYSL5*      2.023 (1.160--3.527)       0.013             Upper 25% vs Lower 25%   CGGAarray   --                      0.026     183   Protein   ([@B35])
  *IL17A*       2.009 (1.107--3.646)       0.022             Upper 50% vs Lower 50%   GSE30472    --                      0.007     41    Protein   ([@B11])
  *TLR9*        1.976 (1.089--3.588)       0.025             Upper 25% vs Lower 25%   CGGAseq     --                      0.020     46    Protein   ([@B36])
  *ACKR3*       1.974 (1.040--3.747)       0.038             Upper 30% vs Lower 30%   GSE7679     1.56 (1.04--2.51)       0.03      146   Protein   ([@B14])
  *H19*         1.864 (1.309--2.653)       \<0.001           Upper 25% vs Lower 25%   Combined    --                      0.034     --    mRNA      ([@B57])
  *EGFR*        1.845 (1.077--3.160)       0.026             Upper 25% vs Lower 75%   GSE7696     --                      \<0.001   196   Protein   ([@B23])
  *NUSAP1*      1.748 (1.006--3.040        0.048             Upper 25% vs Lower 25%   CGGAarray   0.65 (0.49--0.86)\*     0.003     518   mRNA      ([@B44])
  *CHAF1B*      1.707 (1.323--2.203)       \<0.001           Upper 30% vs Lower 30%   Combined    --                      0.004     96    Protein   ([@B13])
  *TAGLN2*      1.665 (1.282--2.161)       \<0.001           Upper 25% vs Lower 25%   Combined    --                      \<0.05    667   mRNA      ([@B20])
  *BIRC1*       1.658 (1.266--2.172)       \<0.001           Upper 25% vs Lower 25%   Combined    --                      0.0003    66    Protein   ([@B48])
  *MGMT*        1.633 (1.260--2.115)       \<0.001           Upper 25% vs Lower 25%   Combined    1.50                    0.01      157   Protein   ([@B12])
  *CD70*        1.561 (1.180--2.065)       0.002             Upper 25% vs Lower 25%   Combined    1.6 (0.98--2.51)        0.046     107   mRNA      ([@B16])
  *CXCR4*       1.558 (1.207--2.010)       \<0.001           Upper 25% vs Lower 25%   Combined    --                      \<0.05    156   mRNA      ([@B32])
  *CA9*         1.556 (1.202--2.015)       \<0.001           Upper 25% vs Lower 75%   Combined    --                      0.004     66    Protein   ([@B7])
  *PDCD1*       1.508 (1.171--1.942)       0.002             Upper 30% vs Lower 30%   Combined    --                      0.028     149   mRNA      ([@B38])
  *IDH1*        1.490 (1.013--2.192)       0.043             Upper 50% vs Lower 50%   CGGAarray   --                      0.045     163   Protein   ([@B8])
  *IGFBP2*      1.467 (1.132--1.902)       0.004             Upper 25% vs Lower 25%   Combined    1.04 (1.02--1.05)       0.001     83    Plasma    ([@B19])
  *PBK*         1.456 (1.131--1.875)       0.004             Upper 25% vs Lower 25%   Combined    --                      0.007     32    Protein   ([@B21])
  *EFEMP2*      1.446 (1.117--1.871)       0.005             Upper 25% vs Lower 25%   Combined    --                      \<0.01    77    mRNA      ([@B28])
  *MET*         1.434 (1.130--1.820)       0.003             Upper 30% vs Lower 30%   Combined    1.7 (1.1--2.2)          \<0.05    69    Protein   ([@B41])
  *CHI3L1*      1.438 (1.104--1.872)       0.007             Upper 25% vs Lower 25%   GSE30472    --                      \<0.01    98    mRNA      ([@B49])
  *TRAF2*       1.443 (1.118--1.863)       0.005             Upper 25% vs Lower 25%   Combined    --                      0.03      105   mRNA      ([@B64])
  *HMGB2*       1.391 (1.099--1.759)       0.006             Upper 30% vs Lower 30%   Combined    3.35 (1.25--9.02)       0.017     51    Protein   ([@B56])
  *MCM6*        1.387 (1.132--1.699)       0.002             Upper 25% vs Lower 75%   Combined    1.19                    0.006     325   mRNA      ([@B6])
  *CD44*        1.386 (1.073--1.790)       0.012             Upper 25% vs Lower 25%   Combined    --                      \<0.001   28    Protein   ([@B49])
  *TIMP1*       1.342 (1.025--1.758)       0.033             Upper 25% vs Lower 25%   Combined    3.2 (1.5--6.7)          0.004     112   Protein   ([@B1])
  *CD151*       1.336 (1.023--1.746)       0.034             Upper 25% vs Lower 25%   Combined    5.064 (1.427--17.969)   0.012     211   Protein   ([@B27])
  *TWIST1*      1.312 (1.013--1.699)       0.039             Upper 25% vs Lower 25%   Combined    5.745 (1.331--1.89)     0.017     86    Protein   ([@B53])
  *CCT6A*       1.316 (1.045--1.655)       0.019             Upper 30% vs Lower 30%   Combined    3.21 (2.85--3.65)       0.006     497   Protein   ([@B18])
  *APC*         1.308 (1.093--1.566)       0.004             Upper 50% vs Lower 50%   Combined    --                      \<0.001   83    Protein   ([@B45])
  *CD247*       1.292 (1.022--1.633)       0.032             Upper 30% vs Lower 30%   Combined    1.54 (1.05--2.28)       0.023     149   mRNA      ([@B38])
  *CXCR3*       1.272 (1.027--1.575)       0.028             Upper 25% vs Lower 75%   Combined    1.56 (1.04--2.51)       0.03      146   Protein   ([@B43])
  *TCTN1*       1.223 (1.011--1.493)       0.039             Upper 30% vs Lower 70%   Combined    1.32 (1.08--1.61)       0.006     518   mRNA      ([@B34])
  *BICD1*       0.794 (0.644--0.978)^\#^   0.030             Lower 25% vs Upper 75%   Combined    1.577 (1.299--1.914)    \<0.001   523   mRNA      ([@B24])
  *IFIT1*       0.770 (0.609--0.973)       0.029             Upper 30% vs Lower 30%   Combined    0.22 (0.10--0.52)       0.001     70    mRNA      ([@B63])
  *BRMS1L*      0.753 (0.587--0.966)       0.026             Upper 25% vs Lower 75%   Combined    --                      \<0.05    60    mRNA      ([@B31])
  *IGF1R*       0.745 (0.588--0.944)       0.015             Upper 30% vs Lower 30%   Combined    1.65 (1.10--2.47)       0.016     167   Protein   ([@B33])
  *GANO1*       0.748 (0.585--0.957)       0.021             Upper 30% vs Lower 30%   Combined    --                      0.009     178   Protein   ([@B67])
  *PTEN*        0.729 (0.567--0.938)       0.014             Upper 25% vs Lower 25%   Combined    3.3 (1.6--4.3)\*        0.0003    61    mRNA      ([@B47])
  *SEMA6A*      0.694 (0.556--0.867)       0.001             Upper 25% vs Lower 75%   Combined    1.71 (1.01--2.65)\*     0.012     200   Protein   ([@B66])
  *PHF3*        0.683 (0.529--0.883)       0.004             Upper 25% vs Lower 25%   Combined    0.44 (0.26--0.77)       0.0031    35    Protein   ([@B60])
  *PPARα*       0.644 (0.503--0.825)       \<0.001           Upper 30% vs Lower 30%   Combined    1.31 (1.05--1.63)\*     0.016     473   mRNA      ([@B22])
  *PCBP2*       0.632 (0.417--0.957)       0.031             Upper 25% vs Lower 75%   TCGA        --                      \<0.001   130   mRNA      ([@B30])
  *LAPTM4B*     0.626 (0.433--0.894)       0.010             Upper 50% vs Lower 50%   TCGA        --                      \<0.001   39    Protein   ([@B15])
  *ANXA7*       0.619 (0.475--0.806)       \<0.001           Upper 25% vs Lower 25%   Combined    --                      \<0.001   99    Protein   ([@B25])
  *PHF20*       0.557 (0.319--0.972)       0.040             Upper 50% vs Lower 50%   CGGAarray   0.5 (0.29--0.86)        0.012     62    Protein   ([@B60])
  *TES*         0.407 (0.173--0.958)       0.040             Upper 30% vs Lower 30%   GSE42669    --                      \<0.05    37    Protein   ([@B3])
  *LGALS1*      0.368 (0.157--0.863)       0.022             Upper 25% vs Lower 25%   GSE42669    --                      0.009     45    Protein   ([@B10])

\*: The lower gene expression compared with higher gene expression in the literature data.

^\#^: The lower gene expression compared with higher gene expression in the OSgbm data.

![Analysis of the prognostic value of *MGMT* in OSgbm. **(A)** The options of input parameters used in the prognostic analysis of *MGMT* in OSgbm. **(B)** The output web page of prognosis analysis of *MGMT* using a combined cohort with pooling all datasets together in OSgbm. **(C)** The OSgbm output of gene *MGMT* in single cohort.](fgene-10-01378-g001){#f1}

Discussion {#s4}
==========

The development of prognostic biomarkers is important for guiding the treatments especially for therapy-resistant GBM patients. In our work, we developed a new web server, OSgbm, to help researchers to evaluate the prognostic value of a given gene for GBM patients. OSgbm is easy to use and requires no special skills (such as bioinformatics training). With filtering by one or several clinical confounding factors provided in OSgbm, users can also evaluate the prognostic value of their interested genes according to their special needs. The function and performance tests of OSgbm web server showed that 96% (51 out of 53) of previously reported prognostic biomarkers could be confirmed in OSgbm, which indicates that these biomarkers validated in independent cohorts have the potency of translating to clinical applications, and also indicates the well performance of OSgbm. Nevertheless, there are two genes including *IGF1R* and *PCBP2* which showed different prognostic values to the literatures, the discrepancy of prognostic performance of *IGF1R* and *PCBP2* between OSgbm and literatures may be caused by race, different cohort size, or analysis level and methods (mRNA vs. protein, gene microarray vs. immunohistochemistry) ([@B33]; [@B30]). For example, the race reported in literatures for *PCBP2* is Asian, while that in validated cohort of OSgbm is mostly White. The mRNA level was analyzed in OSgbm for *IGF1R*, while IGF1R was determined by immunohistochemistry in literature. In addition, the race analyzed in OSgbm for *IGF1R* is Asian (Korea for GSE42669 and Chinese for CGGA), while the race reported in literature for IGF1R is European. As a result, it will be necessary to validate the prognostic performance of *IGF1R* and *PCBP2* in a larger independent cohort of glioblastoma.

In conclusion, OSgbm is a user-friendly web server to help researchers and clinicians to identify suitable prognostic biomarkers in GBM. Furthermore, we will keep update the database of OSgbm to collect more and more GBM datasets when new GBM dataset is available, and will implement the multivariate cox proportional hazards model into OSgbm for the purpose of adjustment for the confounding clinical factors, and we also encourage users to contact us to upload their own data into OSgbm.
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